Ying Dai

1.1k total citations
58 papers, 865 citations indexed

About

Ying Dai is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Ying Dai has authored 58 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 17 papers in Epidemiology and 10 papers in Surgery. Recurrent topics in Ying Dai's work include Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Liver Disease Diagnosis and Treatment (10 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Ying Dai is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (19 papers), Liver Disease Diagnosis and Treatment (10 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Ying Dai collaborates with scholars based in China, United States and Australia. Ying Dai's co-authors include Minhua Chen, Kun Yan, Xuben Yu, Ziye Zhou, Wei Yang, Guanyang Lin, Chunhong Zhang, Wen Gao, Dawei Shi and Kun Yan and has published in prestigious journals such as Journal of Affective Disorders, European Journal of Pharmacology and Medicine.

In The Last Decade

Ying Dai

56 papers receiving 855 citations

Peers

Ying Dai
Moritz von Frankenberg Germany
Sien‐Sing Yang Taiwan
Pujun Gao China
Wolfgang Base Austria
Maria Grazia Scuderi Italy
Josepmaria Argemí Spain
Alexander Zipprich Germany
John Malaty United States
Xiaoling Yang China
Stephen J. Rossi United States
Moritz von Frankenberg Germany
Ying Dai
Citations per year, relative to Ying Dai Ying Dai (= 1×) peers Moritz von Frankenberg

Countries citing papers authored by Ying Dai

Since Specialization
Citations

This map shows the geographic impact of Ying Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Dai more than expected).

Fields of papers citing papers by Ying Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Dai. The network helps show where Ying Dai may publish in the future.

Co-authorship network of co-authors of Ying Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Dai. A scholar is included among the top collaborators of Ying Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Dai. Ying Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dai, Ying, et al.. (2025). Genotype-phenotype insights of pediatric dilated cardiomyopathy. Frontiers in Pediatrics. 13. 1505830–1505830.
2.
Zhang, Chunhong, Furong Li, Ying Dai, et al.. (2024). Risk of immune system and skin and subcutaneous tissue related adverse events associated with oxaliplatin combined with immune checkpoint inhibitors: a pharmacovigilance study. Frontiers in Pharmacology. 15. 1309540–1309540. 2 indexed citations
3.
Wang, Yuzhen, Chuang Chen, Ying Dai, et al.. (2023). Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection. British Journal of Clinical Pharmacology. 90(2). 452–462. 2 indexed citations
4.
Shi, Dawei, et al.. (2022). Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System. British Journal of Clinical Pharmacology. 89(4). 1386–1392. 5 indexed citations
5.
Wu, Fan, Xiaoshan Zhang, Ying Dai, et al.. (2022). Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients. Frontiers in Pharmacology. 13. 844567–844567. 16 indexed citations
6.
Yu, Xuben, Xiaoshan Zhang, Yuzhen Wang, et al.. (2022). Population Pharmacokinetics of Colistin Sulfate in Critically Ill Patients: Exposure and Clinical Efficacy. Frontiers in Pharmacology. 13. 915958–915958. 24 indexed citations
7.
Dai, Ying, Peilin Li, Huan Ma, et al.. (2021). Mibefradil reduces hepatic glucose output in HepG2 cells via Ca2+/calmodulin-dependent protein kinase II-dependent Akt/forkhead box O1signaling. European Journal of Pharmacology. 907. 174296–174296. 4 indexed citations
8.
Wang, Yanjie, Kun Yan, Zhihui Fan, et al.. (2021). Clinical value of contrast-enhanced ultrasound enhancement patterns for differentiating solid pancreatic lesions. European Radiology. 32(3). 2060–2069. 12 indexed citations
9.
Zeng, Yifan, Ying Dai, Ziye Zhou, Xuben Yu, & Dawei Shi. (2021). Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database. Frontiers in Medicine. 8. 648164–648164. 9 indexed citations
10.
Dai, Ying, et al.. (2021). A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature. Journal of Medical Case Reports. 15(1). 41–41. 4 indexed citations
11.
Dai, Ying, Guanyang Lin, & Dawei Shi. (2020). Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. Clinical Therapeutics. 42(5). 940–945. 9 indexed citations
12.
Dai, Ying, Yingying Wang, Yifan Zeng, et al.. (2020). Linezolid and the risk of lactic acidosis: Data mining and analysis of the FDA Adverse Event Reporting System. Journal of Clinical Pharmacy and Therapeutics. 45(6). 1422–1426. 16 indexed citations
13.
Zhang, Haina, Ying Dai, Chunhong Zhang, et al.. (2020). Sirtuins family as a target in endothelial cell dysfunction: implications for vascular ageing. Biogerontology. 21(5). 495–516. 27 indexed citations
14.
Shi, Dawei, et al.. (2019). Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clinical Drug Investigation. 39(9). 847–856. 9 indexed citations
15.
Dai, Ying, et al.. (2019). Tanshinone IIA ameliorates acute lung injury by inhibition of the NLRP3 inflammasome. Archives of Biological Sciences. 71(2). 315–320. 4 indexed citations
16.
Dai, Ying. (2010). Genetic Diversity and Sequence Variation of mtDNA D-loop in the Population of Vulnerable Species Onychostoma lini from the Duliu River. Dongwuxue zazhi. 1 indexed citations
17.
18.
Yang, Wei, Minhua Chen, Maoqiang Wang, et al.. (2008). Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatology Research. 39(3). 231–240. 51 indexed citations
19.
Dai, Ying. (2006). Influence of PBL Instruction on the Educational Environment of Undergraduate Nursing Courses. Journal of Nursing Science. 1 indexed citations
20.
Dai, Ying, et al.. (2006). The role of contrast-enhanced ultrasound on the diagnosis of small hepatocellular carcinoma (≤3cm) in patients with cirrhosis. Hepatology Research. 35(4). 281–288. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Moritz von Frankenberg Breakdown of academic impact, for papers by Sien‐Sing Yang Breakdown of academic impact, for papers by Pujun Gao Breakdown of academic impact, for papers by Wolfgang Base Breakdown of academic impact, for papers by Maria Grazia Scuderi Breakdown of academic impact, for papers by Josepmaria Argemí Breakdown of academic impact, for papers by Alexander Zipprich Breakdown of academic impact, for papers by John Malaty Breakdown of academic impact, for papers by Xiaoling Yang Breakdown of academic impact, for papers by Stephen J. Rossi
Rankless by CCL
2026